The treatment of cancer involves different strategies, such as chemotherapy, surgery, radiation therapy and, most recently, targeted therapies, such as the use of radionuclide-based therapies employed ...

AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

This study utilizes bibliometric analysis to investigate the research landscape of FAP-directed cancer theranostics, focusing ...

Decommissioning, Decontamination, and Technique Development During nuclear decommissioning, radionuclide contaminated materials need to be accurately identified and sentenced for disposal as ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission ...

PRRT is a possible treatment for some NETs that start in the pancreas or the digestive system. It is not a treatment for NECs. Radioisotope therapy uses radioactive medicines to treat some cancer ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.

Diverse Applications: FAPI-based radiotracers have shown promising results in diagnosing various cancers, particularly gastrointestinal malignancies, and have potential applications in inflammatory ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 ...